Benfotyamyn | Benfafa 150 mg1 benfista 1501 pf1fbf1 tablet 30 pcs

Release form

Dragee.

Packing

In the package 30 pcs.

Pharmacological action

Vitamin preparation.

Benfotiamine is a fat-soluble derivative of thiamine (vitamin B1). Thiamine is converted into active thiamine pyrophosphate and, as a coenzyme, is incorporated into pyruvate decarboxylase, alpha-ketoglutarate decarboxylase complexes, which are involved in the oxidative decarboxylation of pyruvic and alpha-ketoglutaric acids transketolase, an enzyme of pentose phosphate shunt.

Indications

Vitamin B1 deficiency, confirmed by clinical and biochemical studies, developing on the background of:

- malnutrition and malnutrition (beriberi disease)

- parenteral nutrition for a long time

- hemodialysis

- chronic alcoholism (alcoholic cardiomyopathy, Wernicke encephalopathy, Korsakoff's syndrome)

- in high demand.

Polyneuropathies due to vitamin B1 deficiency. Typical signs of this deficiency are neurological disorders in the form of neuropathies with sensory disturbances (pain, tingling sensation, loss of sensation in the upper and lower extremities).

Contraindications

- sucrose / isomaltase deficiency, fructose intolerance glucose-galactose malabsorption

- pregnancy

- childhood

- increased individual sensitivity to the components of the drug.

Use during pregnancy and lactation

Pregnancy is a contraindication to the use of the drug.

Special instructions

In older people, adverse reactions other than the above were noted.

It is not recommended to take a double dose of the drug if the previous dose was missed.

With Wernicke encephalopathy, the administration of dextrose should be preceded by taking thiamine.

Influence of the ability to drive vehicles and mechanisms

There is no data on the effect of the drug used in therapeutic doses on the ability to drive vehicles and mechanisms.

Composition

1 tab.

benfothiamine 150 mg

Excipients:

microcrystalline cellulose - 122 mg,

povidone K30 - 8 mg,

fatty acid glycerides - 5 mg,

silicon dioxide colloid - 7 mg,

carmellose 3 mg - 10 mg carmellose sodium .

Shell composition:

shellac - 3 mg,

sucrose - 70.875 mg,

calcium carbonate - 66.479 mg,

talcum powder - 41.314 mg, acridia

gum - 10.155 mg,

corn starch - 7.34 mg,

titanium dioxide - 10.932 mg,

silicon dioxide colloidal - 4.404 mg,

povidone K30 - 6.21 mg,

macrogol 6000 - 1.597 mg,

glycerol 85% - 2.262 mg,

polysorbate 80 - 0.133 mg,

wax mg

Dosage and administration of

For the treatment of vitamin B1 deficiency, 1 tab. 1 time / day

For the treatment of polyneuropathies caused by vitamin B1 deficiency, the initial dose is 1 tab. 2 times / day for 3 weeks, then appoint 1 tab. daily.

The duration of treatment depends on its effectiveness and is determined by the doctor.

Take the tablet without chewing, with a little water.

Side effects

Allergic reactions: angioedema, urticaria, pruritus.

Drug interaction

Thiamine weakens the effect of depolarizing muscle relaxants (suxamethonium iodide and others), and is inhibited by fluorouracil.

Ethanol slows the absorption rate of thiamine after oral administration.

Overdose

Overdose with Benfogam 150 has not been observed so far.

Storage conditions

At a temperature not exceeding 25 РC.

Shelf life

5 years.

tablet dosage form of tablets



Mauermann-Arznaymittel KG, Germany